AdvaMed Comments On Device Center Condition-Of-Approval Study Plans
This article was originally published in The Gray Sheet
Executive Summary
Manufacturers should begin working with FDA to develop postmarket study protocols early in the premarket process, according to CDRH Office of Surveillance & Biometrics Director Susan Gardner
You may also be interested in...
Industry Reps Cite Pitfalls In FDA’s New Approach To Postapproval Studies
The recent shift of responsibility for device condition-of-approval studies to the FDA's Office of Surveillance & Biometrics could result in more elaborate and burdensome study requirements if device firms are not careful, speakers warned at this year's Regulatory Affairs Professionals Society annual meeting
Industry Reps Cite Pitfalls In FDA’s New Approach To Postapproval Studies
The recent shift of responsibility for device condition-of-approval studies to the FDA's Office of Surveillance & Biometrics could result in more elaborate and burdensome study requirements if device firms are not careful, speakers warned at this year's Regulatory Affairs Professionals Society annual meeting
FDA Proposes Status Reports, Web Postings For Postmarket Studies
Device firms should submit interim status reports on mandated post-approval studies to FDA every six months for a study's first two years and annually thereafter, a newly released draft guidance states